Harbin Pharmaceutical Group Co., Ltd. (SHA:600664)

Market Cap	9.37B
Revenue (ttm)	16.16B
Net Income (ttm)	545.17M
Shares Out	2.52B
EPS (ttm)	0.21
PE Ratio	17.66
Forward PE	14.31
Dividend	n/a
Ex-Dividend Date	n/a

Volume	41,785,930
Average Volume	62,945,684
Open	3.740
Previous Close	3.740
Day's Range	3.710 - 3.760
52-Week Range	2.900 - 4.970
Beta	0.17
RSI	32.79
Earnings Date	Aug 23, 2025

About SHA:600664

Harbin Pharmaceutical Group Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, wholesale, and retail of pharmaceuticals in China and internationally. The company offers pharmaceutical products for respiratory, chronic, digestive, blood and hematopoietic, anti-tumor and immunomodulatory, anti-inflammatory and analgesic, anti-virus and anti-infection, cerebrovascular, and cardiovascular diseases, as well as mineral and nutritional supplements, Chinese medicines, and antibiotics. It also provides calcium ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1991
• Employees: 10,180
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 600664

Financial Performance

In 2024, SHA:600664's revenue was 16.18 billion, an increase of 4.65% compared to the previous year's 15.46 billion. Earnings were 628.85 million, an increase of 59.10%.